"JUST DIFFERENT": ZITRO'S ICE BARCELONA 2026 SHOWCASE
"JUST DIFFERENT" isn't just a tagline; it's how Zitro operates, how they build products, and this year, how they're approaching their entire presence at the show. Visitors can expect an equally distinctive experience.
At the heart of the showcase is FANTASY, a cabinet built to attract players from the moment they see it. Representing Zitro's next leap in hardware innovation, FANTASY arrives with an entirely new library of games designed specifically for the platform, featuring spectacular animations, graphics, and multimedia elements that wrap around the gameplay to create a complete entertainment experience.
Alongside FANTASY, Zitro will showcase an expanded game library for its popular CONCEPT cabinet, giving operators even more reliable content to drive floor performance. The enhanced portfolio demonstrates Zitro's commitment to supporting operator success with diverse game options, backed by robust platforms that continue delivering results.
Zitro's digital division continues building momentum with four new game releases debuting at the show: Golden Oink Trio,
"At Zitro, we've built our reputation on approaching the market differently, and ICE Barcelona will showcase that philosophy across every aspect of our business," said
About Zitro
Zitro is a global leader in the gaming industry, widely recognized for its innovative products and exceptional quality. Founded in 2007 by
For more information, please visit www.zitrogames.com or contact us directly. Follow Zitro on LinkedIn, Instagram, Facebook, and X for the latest updates.
Media Contact:
View original content to download multimedia:https://www.prnewswire.com/news-releases/just-different-zitros-ice-barcelona-2026-showcase-302629117.html
SOURCE ZITRO INTERNATIONAL S.A.R.L.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Shanghai Electric Secures First Overseas Heavy-Duty Gas Turbine Order for 500 MW Malaysian Project
- IonOpticks launches Aurora Series® 5 and new CoreJet™ emitter technology, advancing robust nano-LC for routine proteomics research.
- Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share